Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma.
Wong SK, Blum SM, Sun X, Da Silva IP, Zubiri L, Ye F, Bai K, Zhang K, Ugurel S, Zimmer L, Livingstone E, Schadendorf D, Serra-Bellver P, Muñoz-Couselo E, Ortiz C, Lostes J, Huertas RM, Arance A, Pickering L, Long GV, Carlino MS, Buchbinder EI, Vázquez-Cortés L, Jara-Casas D, Márquez-Rodas I, González-Espinoza IR, Balko JM, Menzies AM, Sullivan RJ, Johnson DB. Wong SK, et al. Among authors: buchbinder ei. Eur J Cancer. 2023 Mar;181:188-197. doi: 10.1016/j.ejca.2022.12.013. Epub 2022 Dec 27. Eur J Cancer. 2023. PMID: 36680880
Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma.
Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ. Ott PA, et al. Among authors: buchbinder ei. Nature. 2018 Mar 14;555(7696):402. doi: 10.1038/nature25145. Nature. 2018. PMID: 29542692 Free PMC article.
Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial.
Gogas H, Dafni U, Koon H, Spyropoulou-Vlachou M, Metaxas Y, Buchbinder E, Pectasides E, Tsoutsos D, Polyzos A, Stratigos A, Markopoulos C, Panagiotou P, Fountzilas G, Castana O, Skarlos P, Atkins MB, Kirkwood JM. Gogas H, et al. J Transl Med. 2010 Nov 3;8:108. doi: 10.1186/1479-5876-8-108. J Transl Med. 2010. PMID: 21044351 Free PMC article.
The Phoenix Rises: The Rebirth of Cancer Immunotherapy.
Blasutig IM, Farkona S, Buchbinder EI, Luke JJ, Sharma P, Sznol M. Blasutig IM, et al. Among authors: buchbinder ei. Clin Chem. 2017 Jul;63(7):1190-1195. doi: 10.1373/clinchem.2016.267849. Epub 2017 May 17. Clin Chem. 2017. PMID: 28515097 No abstract available.
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.
Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI. Johnson DB, et al. Among authors: buchbinder ei. JAMA Oncol. 2016 Feb;2(2):234-40. doi: 10.1001/jamaoncol.2015.4368. JAMA Oncol. 2016. PMID: 26633184
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL Jr, Lawrence DP, Logan TF, Schuchter LM, Nair S, Fecher L, Buchbinder EI, Berghorn E, Ruisi M, Kong G, Jiang J, Horak C, Hodi FS. Weber JS, et al. Among authors: buchbinder ei. Lancet Oncol. 2016 Jul;17(7):943-955. doi: 10.1016/S1470-2045(16)30126-7. Epub 2016 Jun 4. Lancet Oncol. 2016. PMID: 27269740 Free PMC article. Clinical Trial.
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.
Buchbinder EI, Gunturi A, Perritt J, Dutcher J, Aung S, Kaufman HL, Ernstoff MS, Miletello GP, Curti BD, Daniels GA, Patel SP, Kirkwood JM, Hallmeyer S, Clark JI, Gonzalez R, Richart JM, Lutzky J, Morse MA, Sullivan RJ, McDermott DF. Buchbinder EI, et al. J Immunother Cancer. 2016 Sep 20;4:52. doi: 10.1186/s40425-016-0155-8. eCollection 2016. J Immunother Cancer. 2016. PMID: 27660706 Free PMC article.
Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma.
Wang DY, Eroglu Z, Ozgun A, Leger PD, Zhao S, Ye F, Luke JJ, Joseph RW, Haq R, Ott PA, Hodi FS, Sosman JA, Johnson DB, Buchbinder EI. Wang DY, et al. Among authors: buchbinder ei. Cancer Immunol Res. 2017 May;5(5):357-362. doi: 10.1158/2326-6066.CIR-16-0287. Epub 2017 Apr 10. Cancer Immunol Res. 2017. PMID: 28396509 Free PMC article.
79 results